Adam Schechter

Adam Schechter became chief executive officer of Labcorp (NYSE: LH) in November 2019 and chairman in May 2020. Previously, Schechter was named lead independent director in January 2019 after serving on the board since 2013.

2024 Developments in Cardiometabolic Care for the Busy Primary Care Physician

The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.

Navigating the nontraditional: A look into fertility challenges and novel referral indications

Hear our subject matter experts share fertility-focused case studies that highlight the challenges and available options for nontraditional families, novel referral indications and how genetic counselors can support patients.

IDWeek

Society for Immunotherapy of Cancer (SITC 2024)

Antibody-drug conjugate (ADC): Providing clarity to complex cancer therapy development

Learn how Labcorp supported development of an ADC targeted chemotherapy and CDx enabling the sponsor to navigate therapy complexity, global trial design and patient selection for a breakthrough cancer treatment.

nAbCyte™ CDx: One-time treatment. Zero room for error.

Learn how Labcorp developed nAbCyte™, the first CDx for a cell-based gene therapy, providing greater access to a potential cure for patients with hemophilia B.

pTau217: Providing critical Alzheimer's diagnosis with key biomarker data

Learn how Labcorp launched pTau217, a highly-accurate blood-based test to detect Alzheimer’s as part of a holistic portfolio of Alzheimer's disease biomarker tests for clinical trial use.

Early phase development solutions: Accelerating answers for a global pandemic

Learn how Labcorp quickly responded to the global COVID-19 pandemic helping a sponsor reduce their IND program from 12 to 5 months. Labcorp further supported Phase I and II trial work for FDA Emergency Use Authorization.

Personalized Medicine Coalition Conference​ (PMC 2024)